Figure 8.

Knockdown of ZNF649-AS1 Reverses Trastuzumab Resistance and Autophagy In Vivo

(A) Representative images of the xenograft after intraperitoneal injection with once every two days 3 mg/kg trastuzumab treatment for 3 weeks in sh-NC or sh-ZNF649-AS1 cell groups. (B) Tumor sizes were calculated every 2 days. (C) Immunohistochemistry analysis revealed that the tumors developed from sh-ZNF649-AS1 cells displayed lower ATG5 staining than did the sh-NC group. (D) GFP staining showed that LC3 puncta was suppressed in ZNF649-AS1-silenced xenograft tissues compared to controlled tissues. (E) The formed autophagosomes were significantly decreased in tumors developed from ZNF649-AS1-silenced cells compared to controlled tissues. ∗∗p < 0.01.